Thiotepa in autologous stem cell transplantation (ASCT): A non-interventional, prospective study to assess safety and efficacy of Thiotepa-based high dose chemotherapy (HDCT) prior to autologous stem cell transplantation in adults with B- or T-cell lymphoma (non-Hodgkin lymphoma or Hodgkin lymphoma) with or without CNS involvement or with primary CNS lymphoma.

Trial Profile

Thiotepa in autologous stem cell transplantation (ASCT): A non-interventional, prospective study to assess safety and efficacy of Thiotepa-based high dose chemotherapy (HDCT) prior to autologous stem cell transplantation in adults with B- or T-cell lymphoma (non-Hodgkin lymphoma or Hodgkin lymphoma) with or without CNS involvement or with primary CNS lymphoma.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Thiotepa (Primary)
  • Indications B cell lymphoma; Hodgkin's disease; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors RIEMSER Arzneimittel
  • Most Recent Events

    • 24 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top